





BEST AVAILABLE COPY**POLYPEPTIDES (3-4 AMINO ACIDS) WITH ANTIOXIDANT MOIETIES
COVALENTLY ATTACHED AND THEIR USE AS PULMONARY SURFACTANTS**

Patent number: NZ254496
Publication date: 1996-08-27
Inventor: MCLEAN LARRY RAYMOND; EDWARDS JUDSON VINCENT
Applicant: MERRELL DOW PHARMA
Classification:
- international: **C07K5/113; C07K14/785; A61K38/00; C07K5/00; C07K14/435; A61K38/00; (IPC1-7): C07K5/06; A61K38/05; A61K38/06; A61K38/07; C07K5/08; C07K5/10**
- european: **C07K5/10C; C07K14/785**
Application number: NZ19930254496 19930630
Priority number(s): US19920923092 19920731; US19930077802 19930621


Also published as:

 WO9403484 (A1)
 EP0652894 (A1)
 EP0652894 (B1)
 CA2137348 (C)

Report a data error here

Abstract not available for NZ254496
Abstract of corresponding document: **WO9403484**

Synthetic pulmonary surfactants having antioxidant properties consisting of a complex of a polypeptide of 3-4 amino acid residues, with an antioxidant moiety, and a lipid consisting of one or more of the lipids associated with natural pulmonary surfactant were prepared. These surfactants are useful in the treatment of respiratory distress syndrome.

**HBB-Aoc-Glu-Trp-Ala-Lys-NH₂**



Data supplied from the esp@cenet database - Worldwide



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 5/10, 5/08, 5/06 A61K 37/02		A1	(11) International Publication Number: WO 94/03484
			(43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/US93/06249		(74) Agent: COLLIER, Kenneth, J.; Marion Merrell Dow Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).	
(22) International Filing Date: 30 June 1993 (30.06.93)			
(30) Priority data: 07/923,092 31 July 1992 (31.07.92) US 08/077,802 21 June 1993 (21.06.93) US		(81) Designated States: AU, CA, FI, HU, JP, KR, NO, NZ, Eu- ropean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant: MERRELL DOW PHARMACEUTICALS INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).		Published <i>With international search report.</i>	
(72) Inventors: McLEAN, Larry, R. ; 37 West Charlotte Ave- nue, Cincinnati, OH 45215 (US). EDWARDS, J., Vin- cent ; 1086 Lanny Lane, Cincinnati, OH 45231 (US).			

(54) Title: SYNTHETIC PEPTIDE LUNG SURFACTANTS HAVING COVALENTLY BONDED ANTIOXIDANTS



(57) Abstract

Synthetic pulmonary surfactants having antioxidant properties consisting of a complex of a polypeptide of 3-4 amino acid residues, with an antioxidant moiety, and a lipid consisting of one or more of the lipids associated with natural pulmonary surfactant were prepared. These surfactants are useful in the treatment of respiratory distress syndrome.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

-1-

5

SYNTHETIC PEPTIDE LUNG SURFACTANTS
HAVING COVALENTLY BONDED ANTIOXIDANTS

FIELD OF THE INVENTION

10 This is a continuation-in-part of application Serial
No. 07/923,092, filed July 31, 1992.

 This invention relates to the synthesis of a series of
3 to 4 amino acid polypeptides having antioxidants
15 covalently linked to the peptide either directly or through
a linker region. These modified peptides are useful as
synthetic lung surfactants having useful antioxidants
structurally as part of the peptide. Also described are
the preparation of mixtures of these polypeptides with
20 lipids, the method for production of same, and
pharmaceutical compositions which are effective in the
treatment of mammalian respiratory distress syndromes.

BACKGROUND OF THE INVENTION

25

 The lungs exist in a delicate balance between toxic
oxidants and the protective activities of antioxidant
defense systems. An imbalance in this system, either
through an increase in oxidants or a dysfunction of the
30 protective antioxidant defense systems, can lead to
pathophysiological events in the lung causing pulmonary
dysfunction. One type of pulmonary dysfunction in which an
increase in oxidants can contribute is respiratory distress
syndrome (RDS).

35

-2-

Infantile respiratory distress syndrome is a leading cause of death in the first 28 days of life. Infantile RDS strikes 1 in 100 babies worldwide and about 10 percent die. The syndrome rarely occurs in term infants but is generally associated with immaturity and low-birth weight (under 2 kg). Adult RDS shows similar clinical characteristics and pathophysiology to the infantile disease and is generally managed in an intensive care facility. The adult disease has diverse etiologies, many resulting from lung insults, such as diffuse infections, aspiration of the gastric contents, inhalation of irritants and toxins, and pulmonary edema arising from such sources as narcotic overdose.

RDS is correlated with an absence or dysfunction of the lung surfactant which coats the alveoli of the lungs where gas exchange occurs, and has been associated with oxygen centered free radicals in the lung or lung cavity known as oxidants, such as superoxide radicals, hydroxyl radicals, hydrogen peroxide which can generate hydroxyl radicals, and lipid peroxides, which have been implicated in cellular injury (Heffner, et al., Am. Rev. Respir. Dis. 104: 531-554 1989); (Halliwell, FASEB J. 1: 358-364 1987).

Synthetic lung surfactant of larger polypeptides having antioxidant moieties, have been described in U.S. Patent application serial no. 07/789,918 filed November 4, 1991, which is herein incorporated by reference. However, the present invention provides an effective synthetic lung surfactant having antioxidant properties to shortened peptides of 3-4 amino acids having the ability to inhibit oxidation of susceptible compounds into oxidants. The shortened lung surfactants provide a more efficient and more cost effective means of producing therapeutics. The present novelty of the invention resides in the ability to effectively reduce the peptide to 3-4 amino acids with the

retention of surfactant properties and effectively deliver the peptide attached to a covalently bonded antioxidant.

Some synthetic lung surfactant preparations have added
5 therapeutic agents such as Vitamin E to surfactant
preparations as a separate component (U.S. Patent No.
4,765,987; PCT Publication No. WO 90/11768; PCT publication
no. WO 90/07469). However, in the present invention the
antioxidants are not a separate component but are actually
10 incorporated into a polypeptide. An advantage of
incorporating the antioxidant into the polypeptide is that
instead of having a three component mixture (lipid,
polypeptide and antioxidant), a two component mixture is
available. This can be a significant advantage in testing
15 for efficacy for a marketable pharmaceutical where a
variety of dosages and formulations must be tested for each
component. Additionally, a two component formulation is
easier to manufacture.

20 The polypeptides of the present invention may be used
singly in mixtures with lipid or in combination in mixtures
of lipid wherein the polypeptide comprises a minor
component of the surfactant mixture. The composition of
the present invention may be prepared in high purity and in
25 a standardized fashion as it is a defined mixture of
synthetic components. Also, the components are not derived
from animal sources which minimizes the risk of
contamination by viruses and bacteria.

30 A helical wheel representation of an amphipathic α -
helical ten-residue peptide (for description of the
amphipathic α -helical peptide see McLean, L.R. et al.
Biochem., 1991, 30, 31) is used to develop a model for
three and four residue peptides. When looking down the
35 barrel of the α -helix, the side chains of the residues

indicate a hydrophobic face and a hydrophilic face on the helix. A four residue peptide represents a single turn of this α -helix with the required hydrophobic and hydrophilic face present. A three residue peptide represents a
5 constricted turn of the α -helix with the hydrophobic and hydrophilic face still present.

10

15

20


25

30

35

SUMMARY OF THE INVENTION

The present invention comprises synthetic lung surfactants consisting of a complex of a polypeptide and lipids wherein the polypeptide has the following formula 1:



1

or an optically active isomer or pharmaceutically acceptable salt thereof; wherein


A_1 is a bond or negatively charged amino acid selected from Glu or Asp;

A_2 is a hydrophobic amino acid selected from Trp, Tyr, Phe, His, Val, Leu, or Ile;


A_3 is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and

A_4 is a positive charged amino acid selected from Lys, Arg, or His;

X is of formula Da or Db:



Da



or

Db


wherein, B_1 is B, $-C(O)-$, $-B-C(O)-$, $-C(O)-NH-B-C(O)-$; and B is a bond, C_{1-16} alkylene, or C_{2-16} alkenylene; and wherein each R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 is independently a C_{1-6} alkyl;

Y is a carboxyl substituent of A_4 selected from hydroxy, amino, alkylamino, and alkoxy groups; and

-6-

wherein, when A₃ is a bond, A₁ and A₂ may be
interchanged.

In addition the present invention comprises synthetic
5 lung surfactants consisting of a complex of a polypeptide
and lipids wherein the polypeptide has the following
formula 2:



10

or an optically active isomer or pharmaceutically
acceptable salt thereof; wherein

A₁ is a bond or Glu;


A₂ is Trp or Glu;

15 A₃ is Aib, Glu, Gln, Leu, Ala or Orn; and


A₄ is Lys;

X is of formula Da or Db:

20



Da



Db

25

wherein B₁ is B, -C(O)-, -B-C(O)-, -C(O)-NH-B-C(O)-;
and B is a bond, C₁₋₁₆ alkylene, or C₂₋₁₆
30 alkenylene; and wherein each R₁, R₂, R₃, R₄, R₅, R₆
and R₇ is independently a C₁₋₆ alkyl; and

Y is a carboxyl substituent of A₄ selected from
hydroxy, amino, alkylamino, and alkoxy groups.

35

-7-

Further the peptides of this invention may be associated with a lipid, comprised of one or more of the type associated with natural pulmonary surfactant.

- 5 These polypeptide-lipid complexes and their pharmaceutical compositions are useful in treating mammalian respiratory distress syndrome.

BRIEF DESCRIPTION OF THE DRAWINGS

10

Figure 1 is a helical wheel representation of a ten-residue peptide surfactant used to develop a model for short peptides. The view is down the barrel of the helix and the side chains of the residues are indicated in their positions relative to the axis of the helix. The hydrophobic face includes the residues to the right in the drawing which are Trp⁸, Leu¹, Leu⁵, Leu⁹, Leu² and Leu⁶. The hydrophilic face includes the charged residues Lys⁴, Glu⁷, Glu³ and Lys¹⁰.

20

Figure 2 is an example of a tetrapeptide antioxidant designed on the basis of a single turn of the helical wheel projection of the ten-residue peptide shown in Figure 1. The hydrophobic face of the Figure 1 peptide has been replaced by Trp², Ala³, HBB-Aoc which present a sufficient hydrophobic face to anchor the peptide to the lipid. The hydrophilic charged face has been replaced by Glu¹ and Lys⁴.

30

BRIEF DESCRIPTION OF TABLES

Table I shows the results from amino acid analysis of the synthesized peptides.

Table II shows the results of pressure-volume

35

experiments showing the effectiveness of compounds in the adult rat lung model.

DETAILED DESCRIPTION OF THE INVENTION

5

The following common abbreviations of the naturally occurring amino acids are used throughout this specification:

10

Ala or A - alanine
Val or V - valine
Leu or L - leucine
Ile or I - isoleucine
15 Phe or F - phenylalanine
Trp or W - tryptophan
Met or M - methionine
Ser or S - serine
Tyr or Y - tyrosine
20 Asp or D - aspartic acid
Glu or E - glutamic acid
Gln or Q - glutamine
Thr or T - threonine
Gly or G - glycine
25 Lys or K - lysine
Arg or R - arginine
Asn or N - asparagine
Nle - norleucine
Orn - ornithine
hArg - homoarginine
30 Nva - norvaline
Aib - amino-isobutyric acid

30

The natural amino acids, with the exception of glycine,
35 contain a chiral carbon atom. Unless otherwise specifi-

cally indicated, the optically active amino acids, referred to herein, are of the L-configuration. Once the antioxidant moiety of the present invention is added to the peptide, stereoisomers can be formed. The present
5 invention comprises mixtures of such stereoisomers as well as the isolated stereoisomer. As is customary, the structure of peptides written out herein is such that the amino terminal end is on the left side of the chain and the carboxy terminal end is on the right side of the chain.

10

When two amino acids combine to form a peptide through a typical amide bond, a molecule of water is released, and what remains of each amino acid is called a "residue". The amide linkage can also occur when X is linked to a
15 subsequent amino acid or to an amide bond isoster. A residue is therefore an amino acid that lacks a hydrogen atom of the terminal amino group, and lacks the hydroxyl group of the terminal carboxyl group. Using accepted terminology, a dash (-) in front of (indicating loss of a
20 water) a three letter code for an amino acid or amino acid derivative indicates the amine bond of a residue.

"Alkyl" as used herein means a straight or branched chain hydrocarbon radical such as methyl, ethyl, propyl,
25 butyl, isopropyl, tert-butyl, sec-butyl, isopentyl, 1-methylbutyl and so on, depending upon the number of carbon atoms specified. "Acyl" as used herein means a radical formed from an organic acid by removal of a hydroxyl group; the general formula is RCO- where R may be aliphatic,
30 alicyclic, aromatic hydrocarbon or hydrogen (formyl group). The R group may be substituted. An example of an acyl group is succinyl.

As used herein the term "hydrophobic amino acid" means
35 a nonpolar residue with an aliphatic hydrocarbon side chain

such as Val, Leu or Ile; or a nonpolar residue with an aromatic group such as Phe, Tyr, Trp or His.

As used herein the term "negatively charged amino acid" means a polar residue with an acidic hydrophilic side chain such as Glu or Asp.

As used herein the term "positive charged amino acid" means a polar residue with a basic hydrophilic side chain such as Lys, Arg or His.

Peptides, where X has not been functionally modified by the designated antioxidant, can be synthesized by any suitable method such as solid phase sequential procedure, described hereafter. Preferred Markush groups are where, R_1 , R_2 , R_6 and R_7 are each tert-butyl, and each of R_3 , R_4 and R_5 are methyl. Da is preferable to Db, and B is preferably $-C(O)-NH-B-C(O)-$, wherein B is a C_8 alkane;

X is referred to herein as "antioxidant moiety" because it is believed that X is that portion which confers antioxidant properties on the polypeptide. However, it is to be understood that X may have linkers to the polypeptide so that when antioxidant moieties attached to the polypeptide are described, it also includes the appropriate linkers, e.g., B, $-C(O)-$, $B-C(O)-$, $C(O)-NH-B-C(O)-$, etc.

There are many ways to form X. For example, amino acid derivatives can be acylated by an acylating agent formed from antioxidant compounds. To be an acylating agent, the antioxidant compounds can, for example, form a symmetrical anhydride or an active ester, e.g., N-hydroxybenzotriazole ester (HOBt ester). The acylating agent is then exposed to the unprotected functional nucleophile for the reaction to take place. This is preferably performed in solid phase

peptide synthesis while the amino acid to receive the antioxidant moiety is part of the peptide attached to the resin.

5 Individual amino acids can also be modified prior to incorporation into the peptide by, for example, esterification, reductive alkylation, etc. Other modifications of amino acids and amino acid derivatives containing functional groups are well known in the art.

10

 Preferred examples of antioxidant compounds found to be useful in reacting with amino acids or amino acid derivatives in the present invention are as follows:

- 15 1) HBB = 3,5-di-t-butyl-4-hydroxybenzoic acid
 2) HBP = 3-(3',5'-di-tert-butyl-4-hydroxyphenyl)-
 propionic acid
 3) HBC = 3,5-di-tert-butyl-4-hydroxycinnamic acid

20 4) HBA = 2-(3',5'-di-t-butyl-4-hydroxyphenyl) acetic
 acid
 5) di-HBA = 2,2-di-(3',5'-di-t-butyl-4-hydroxyphenyl)-
 acetic acid


25 6) Trl = 6-hydroxy-2,5,7,8-tetramethylchroman-2-
 carboxylic acid -also known as Trolox

 Preferably HBB, HBP, HBC, HBA, di-HBA, and Trl are used when the functional group is either an alcohol group or an
30 amino group. Within the group of linked surfactants a preferred grouping can be selected to form a more preferred grouping, such as, HBB and Trl.

 The foregoing antioxidant compounds are commercially
35 available or the synthesis known in the art, e.g., 3,5-di-

t-butyl-4-hydroxyphenylacetic acid is described in Izv. Akad. Nauk SSSR, Ser. Khim., 358 1965 and 3,5-di-t-butyl-4-hydroxy-benzaldehyde is described in J. Org. Chem., 22, 1333 1957. Generally, any antioxidant compound may be used
 5 in the present invention which (1) can be attached to the polypeptide of the present invention, (2) exhibits antioxidant activity while attached to the polypeptide, and (3) permits the polypeptide to perform as described herein.

10 Trl-Glu - means a molecule having a peptide bond formed between trolox and a glutamyl residue; wherein the trolox is attached to the α-amino group of a Glutamic acid residue as shown below:



20 As shown by the Trl-Glu example, the antioxidant moiety, in this case where X = Db and B = a bond, together with a carbonyl group (C(O)-) can be attached to the α-amino terminus of polypeptide to form Db-C(O)-A₁-A₂-A₃-A₄-Y.

25 The polypeptides of this invention can be prepared by a variety of procedures readily known to those skilled in the art such as solution phase chemistry. A preferred method is the solid phase sequential procedure which can use
 30 automated methods such as the ABI peptide synthesizer. In solid phase sequential procedure, the following steps occur: (1) a first amino acid, having a protected α-amino group, is bound to a resin support; (2) the carboxylic group of a second amino acid, having a protected α-amino
 35 group, is activated; (3) the first amino acid is

deprotected with a reagent which permits the first amino acid to remain attached to the resin; and (4) coupling occurs between the α -amino group of the first amino acid and the activated carboxylic group of the second amino acid. These steps are repeated with new amino acid residues which permits the formation of the peptide. When the desired length of peptide has been formed, the peptide may be modified with an appropriately coupled antioxidant moiety prior to being cleaved from the resin, deprotected and isolated. Alternatively the protected peptide may be selectively removed from the resin, and the antioxidant moiety is coupled to the peptide prior to removal of protecting groups and isolation.

The resin support employed can be any suitable resin conventionally employed in the art for the solid phase preparation of polypeptides such as a polystyrene which has been cross-linked with from 0.5 to about 3 percent divinyl benzene, which has been either chloromethylated or hydroxymethylated to provide sites for ester formation with the initially introduced α -amino protected amino acid. Other suitable resin supports are PMHBA (Peptide International, Louisville, Ky), RINK (Calbiochem, LaJolla, Ca) and Sasrin (Biochem, Philadelphia, Pa). The Sasrin resin requires a special ABI cycle for loading the first amino acid which is described in the ABI peptide synthesizer user's manual. The first amino acid, having a protected α -amino group, is attached to the resin as described in the Applied Biosystems Model 430A Peptide Synthesizer User's Manual, incorporated in its entirety herein.

Preferred methods of activating each added amino acid to the bound peptide chain include formation of a symmetrical anhydride or active ester of the each added α -

amino, which has been appropriately protected. For example, an α -amino protected amino acid can be reacted with dicyclohexylcarbodiimide (DCC) in the presence of dichloromethane (DCM) to form the symmetrical anhydride.

5 Alternatively, a HOBT active ester can be formed by dissolving Boc-amino acid (tert-butyloxycarbonyl-amino acid) and HOBT in DCC and chilling, adding additional DCC and warming the solution to room temperature. This solution is then added to the amino acid bound resin. This

10 method of activation to form acylating agents may also be used for the antioxidant compounds.

If there are other functional groups present besides the α -amino group, those groups will generally have to be

15 protected. Generally, the α -amino group and each of the side chain functional groups can be protected by different protecting groups so that one protecting group can be removed without removing the other protecting groups.

20 Among the classes of α -amino protecting groups contemplated for use with the present invention are (1) acyl type protecting groups such as: formyl, trifluoroacetyl, phthalyl, toluenesulfonyl (tosyl), benzenesulfonyl, nitrophenylsulfenyl, tritylsulfenyl, o-

25 nitrophenoxyacetyl and γ -chlorobutyryl; (2) aromatic urethan type protecting groups such as benzyloxycarbonyl and substituted benzyloxycarbonyl such as p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, 1-(p-

30 biphenyl)-1-methylethoxycarbonyl, α,α -dimethyl-3,5-dimethoxybenzyloxycarbonyl and benzylhydroxycarbonyl; (3) aliphatic urethan protecting groups such as tert-butyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl and allyloxycarbonyl;

35 (4) cycloalkyl urethan type protecting groups such as

cyclopentyloxycarbonyl or 9-fluorenylmethoxycarbonyl (Fmoc); (6) alkyl type protecting groups such as triphenylmethyl (trityl) and benzyl; (7) trialkylsilane groups such as trimethylsilane.

5

The selection of the α -amino protecting group, however, will depend upon the resin used, the target site functional group, the other functional groups present in the polypeptide and whether the amino acid derivative X can
10 withstand cleavage from the resin with the cleavage reagent. For example, to prepare HBB-Aoc-Glu-Trp-Aib-Lys-NH₂, (SEQ ID NO: 1), a PMBHA resin is used, which produces a C terminal amino group, and the peptide is constructed
15 synthesizer. The HBB moiety can be introduced as an HOBT active ester in order to attach HBB at the target site N- α -amino group of Glutamic acid. Anhydrous hydrofluoric acid (HF) can be used to simultaneously cleave the peptide from the resin and to remove the remaining protecting groups.

20

The selection of appropriate combination of protecting groups and reagents to selectively remove protecting groups is well known in the art. For example, see M. Bodanszky, PEPTIDE CHEMISTRY, A PRACTICAL TEXTBOOK, Springer-Verlag
25 (1988); J. Stewart, et al., SOLID PHASE PEPTIDE SYNTHESIS, 2nd ed., Pierce Chemical Co. (1984).

Each protected amino acid or amino acid sequence is introduced into the solid phase reactor in about a four-
30 fold excess and the coupling is carried out in the presence of a coupling agent such as in a medium of dimethylformamide: methylene chloride (1:1) or in dimethylformamide alone or methylene chloride alone. In cases where incomplete coupling occurs, the coupling procedure is
35 repeated before removal of the α -amino protecting group,

prior to the coupling of the next amino acid in the solid phase reactor. The success of the coupling reaction at each stage of the synthesis is monitored by the ninhydrin reaction as described by E. Kaiser, et al., Analyt.

5 Biochem. 34, 595 (1970).

After the desired amino acid sequence has been obtained, the peptide is removed from the resin using any appropriate reagent which will not adversely effect the
10 polypeptide. For example, anhydrous HF containing 5% anisole and 5% acetonitrile in 0.1% trifluoroacetic acid can be used to cleave the polypeptide from a pMBHA resin.

The polypeptides of Formula 1 can form pharmaceutically
15 acceptable salts with any non-toxic, organic or inorganic acid. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
20 Illustrative organic acids which form suitable salts include the mono, di and tricarboxylic acids. Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic,
25 hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid. Salts of the carboxy terminal amino acid moiety include the non-toxic carboxylic acid salts formed with any suitable inorganic or
30 organic bases. Illustratively, these salts include those of alkali metals, as for example, sodium and potassium; alkaline earth metals, such as calcium and magnesium; light metals of Group IIIA including aluminum; and organic primary, secondary and tertiary amines, as for example,
35 trialkylamines, including triethylamine, procaine,

dibenzylamine, 1-ethenamine, N,N'-dibenzylethylenediamine, dihydroabietylamine, N-(lower)alkylpiperidine, and any other suitable amine.

5 The phospholipids of the protein-phospholipid complexes of this invention can be any phospholipid and this term as used herein includes the phosphoglycerides and the sphingolipids. Phosphoglycerides are those di-fatty acid esters of glycerol in which the remaining hydroxy group, a
10 terminal hydroxy group, of the glycerol moiety forms an ester with phosphoric acid. Commonly the phosphoric acid moiety of the phosphoglycerides forms a second ester with an alcohol such as ethanolamine, serine, choline, or glycerol. Sphingolipids are those mono-fatty acid esters
15 of sphingosine or dihydrosphingosine in which the hydroxy group at the 1-position forms an ester with the choline ester of phosphoric acid. The preferred lipids of the protein-phospholipid complexes of this invention comprise dipalmitoylphosphatidylcholine (DPPC), phosphatidylcholine
20 molecules containing acyl chains of other lengths and degrees of saturation (PC), cardiolipin (CL), phosphatidylglycerols (PG), phosphatidylserines (PS), fatty acids (FA), and triacylglycerols (TG). DPPC comprises the major component of the lung surfactant mixture while PC,
25 CL, PG, PS, FA, and TG comprise minor components. Suitable fatty acids for use in the phospholipids of this invention are long chain carboxylic acids (generally having eight or more carbon atoms), typically unbranched. The fatty acids can be either saturated or unsaturated. Representative
30 fatty acids are lauric, myristic, palmitic, and oleic acids.

Pharmaceutical preparations of the polypeptide or the protein-phospholipid complexes of this invention can be
35 prepared as a dry mixture or in an aqueous suspension, in

some instances containing small amounts of organic solvents, such as, for example, ethanol or trifluoro-ethanol, detergents, such as, for example, sodium dodecyl sulfate or sodium deoxycholate, salts, such as calcium chloride or sodium chloride, carbohydrates, such as glucose, dextrose or mannitol, and amino acids, such as glycine and alanine. Where the pharmaceutical composition is made into liquid form, stabilizers, preservatives, osmotic pressure regulators, buffering agents, and suspending agents of the liquid may be added. If desired, suitable germicides may also be added. The pH of the aqueous suspension may vary between 2 and 10 and may be adjusted with acids and bases, such as, for example, hydrochloric acid, sodium phosphate, or sodium hydroxide.

The dry mixture may be reconstituted in an aqueous solution containing pharmaceutically acceptable salts, organic solvents, and detergents. The aqueous preparation may be dialyzed, filtered, or chromatographed to exchange the suspending medium with a pharmaceutically acceptable medium prior to use. The preparation may be administered as a dry powder, an aqueous suspension, or as an aerosol directly into the lungs of the distressed subject. The pharmaceutical composition of the present invention may be charged in hermetically sealed containers such as vials and ampules and be preserved sterilely. The composition may be stored in a vial or ampule separately from a vial or ampule containing the suspension buffer and the dry or hydrated composition may be mixed with the suspension buffer prior to use.

30

Lipid constitutes from 50 to 99.9% of the lung surfactant preparation. Suitable lipids include DPPC, PC, CL, PG, PS, FA, and TG. DPPC comprises the major lipid species and is present in concentrations of 60 to 100% of the total lipid weight. The remaining lipids are present

35

in minor concentrations. PC, CL, PG and PS may comprise up to 30% of the lipids, and FA and TG may comprise up to 10% of the lipid weight. The fatty acyl chains of the minor lipid components may be saturated or unsaturated and of any chain length. Chain lengths of 12 to 16 carbon atoms and up to 2 unsaturated bonds are preferred. The preferred lipid composition is 85-100% DPPC plus 0-15% of PG. Most preferred is pure DPPC.

10 The lipid components of the synthetic lung surfactant are commonly found in mammalian lung surfactant and are available from common industrial sources in high purity. The polypeptide components are prepared by solid-phase peptide synthesis by methods familiar to those skilled in the art. Mixtures of the lipids of the invention with proteins isolated from mammalian lung lavage have been shown to be effective in treating neonatal RDS. However, mixtures of these lipids with synthetic peptides in lung surfactant preparations has only recently been reported
15
20 (McLean, et al.).

Lipids are suspended as liposomes by methods familiar to those skilled in the art; i.e., wherein initially lipids are mixed in a volatile organic solvent or mixtures of solvents, such as mixtures of chloroform and methanol or trifluoroethanol. The organic solvent is removed by evaporation under nitrogen, argon, or under vacuum. An aqueous solution which may contain organic and inorganic acids, bases, and salts, and saccharides such as dextrose
25
30 is added to the dry lipid mixture to attain a final concentration of 0.1 to 100 mg of DPPC per ml. In general, it is preferable, but not necessary to warm the mixture to 35-50°C, mix vigorously, and incubate for up to 2 hours at 25-50°C. Then, peptide or a mixture of peptides is added
35 as a dry powder or suspended in an aqueous solution in some

cases containing a suitable organic solvent, such as ethanol or trifluorethanol, or a denaturing agent, such as guanidinium hydrochloride or urea, which improves the solubility of the peptide in the aqueous suspension.

- 5 Association of peptide and lipid may be promoted at a particular pH, thus the pH of the aqueous solution may vary from 2 to 10. The preferred method for mixing peptide and lipid is to add dry peptide to lipid in water at 45-50°C and to mix by bath ultrasonication at 45-50°C for 30-90
10 minutes, then freeze-dry and store at -20°C.

- Lipids can optionally be mixed with a suitable detergent such as octylglucoside or sodium deoxycholate at a weight ratio of from 1 to 20 parts of detergent per part
15 of DPPC in water, an aqueous buffer, or saline solution at concentrations from 1 to 100 mg DPPC/ml. Then, peptide is added as a dry powder or suspended in an aqueous solution with or without an organic solvent, denaturing agent, or detergent. The mixture is then dialyzed, filtered,
20 centrifuged or chromatographed to remove the detergent.

- Preferably, lipids and peptides are mixed in a volatile organic solvent with or without a small amount of water. The volatile solvent is evaporated under a stream of
25 nitrogen or argon, in a vacuum oven, or by rotary evaporation either before or after addition of an aqueous solvent.

- The mixture of lipid and peptide prepared by one of the
30 methods described above is incubated for up to 2 hours, preferably at 35-50°C with sonic irradiation. The mixture may then be dialyzed, filtered, or chromatographed to replace the aqueous medium with a pharmaceutically acceptable medium, although this is not necessary. In some
35 cases, efficacy is improved by separating unreacted lipid

or peptide from associated lipid and peptide by ultracentrifugation, filtration, or chromatography. The mixture may then be lyophilized or aerosolized.

5 When the polypeptide-phospholipid complexes of this invention are used in the treatment of neonatal respiratory distress syndrome, a physiological condition which results from the inability of the lungs of premature infants to produce pulmonary surfactant, the complexes act as an
10 antioxidant and synthetic pulmonary surfactants and either replace the natural, missing surfactant or augment the lack of sufficient natural surfactant. Treatment is continued until the infant's lungs produce a sufficient amount of natural, pulmonary surfactant so as to render further
15 treatment unnecessary.

The preparations are preferably those suitable for endotracheal administration, that is as a liquid suspension, a dry powder, or an aerosol. For a liquid
20 suspension, the dry mixture or the mixture in aqueous suspension is mixed with suitable agents, such as water, saline solutions, dextrose, and glycerol to produce a pharmaceutically effective composition. Preferred liquid suspensions will contain 0.8 to 1.0 weight per cent of
25 sodium chloride and will be 1 - 20 mM, preferably in calcium ion. The preparation is then filter sterilized. In general, the preparation comprises 1 to 100 mg of DPPC per ml and is administered at a dose of 0.2 to 5 ml/kg. To prepare a dry mixture, the aqueous suspension is
30 lyophilized. The aerosol is prepared from a finely divided dry powder suspended in a propellant, such as lower alkanes and fluorinated alkanes, such as Freon. The aerosol is stored in a pressurized container.

For example, the surfactant (polypeptide of the present invention and lipid complex) is administered, as appropriate to the dosage form, by endotracheal tube, by aerosol administration, or by nebulization of the suspension or dry mixture into the inspired gas. The surfactant is administered in one or multiple doses of 10 to 200 mg/kg. The preferred method of administration is as a suspension of peptide and lipid in physiological saline solution at a concentration of 5-10 mg of surfactant per ml through an endotracheal tube, achieving a dose of 50-100 mg/kg.

The polypeptide of the present invention is administered to treat a subject. "Subject" means a mammal, for example, but not limited to, a human being.

The following examples show some methods of preparation for the polypeptide, polypeptide/lipid complex and starting materials of the present invention. The present invention is not limited to the following examples nor to these methods of preparation.

Abbreviations used in the examples not previously defined are as follows:

TBDMS Tetrabutyl dimethylsilyl
SEt Ethylthio
Suc Succinyl
TFA Trifluoroacetic acid
Bzl Benzyl
Ot-Bu t-butyl ether;

which accompany standard Boc chemistry and standard Fmoc chemistry: that chemistry used with the ABI peptide synthesizer respectively for the Boc cycles and the Fmoc cycles.

EXPERIMENTAL CHEMICAL PROCEDURES

EXAMPLE 1

5 Peptide Synthesis and other Chemicals. Peptides were synthesized on a 0.5 mmol scale by solid-phase methods on an Applied Biosystems Inc. (Foster City, CA) Model 430-A peptide synthesizer. p-methylbenzoxyhydramine (pMBHA) resin was used to give C-terminal amides on cleavage. Na-t-
10 Boc (t-butyloxycarbonyl) amino acids with side chain protection Cys(ethylthio), Glu(benzyl) and Lys(2-chlorobenzoyloxycarbonyl) from Peptides International were double-coupled via their preformed symmetrical anhydrides. The antioxidant group, was coupled by activating the acid of
15 the antioxidant to form the symmetrical anhydride. Antioxidants, such as HBB (3,5, di-tert-butyl-4-hydroxy benzoic acid) were placed at the amino terminus of the peptide by preactivating the HBB acid to form the
20 corresponding symmetrical anhydride. Generally the antioxidant was double or triple coupled to assure complete reaction. For example HBB required three couplings to achieve complete incorporation. Additional couplings were performed as determined based on ninhydrin tests. Na-t-Boc groups were removed with 50% trifluoroacetic acid (TFA) in
25 methylene chloride and neutralized with 10% diisopropylethylamine (DEA) in dimethyl formamide. The peptides were cleaved from the resin and deprotected in anhydrous HF containing 5% anisole and 5% dimethyl sulfide at -5°C for 45 min. HF was removed in vacuo and the peptide
30 extracted from the resin with 50% aqueous acetonitrile. The combined extracts were frozen and lyophilized and purified by reverse phase preparative HPLC on a Rainin Dynamax (21.4 x 250 mm) C₁₈ column at 40 mL/min with an acetonitrile gradient in 0.1% aqueous TFA (pH 2) monitored at 214 nm.

35

The major peak was collected and lyophilized. The purity (>97%) and identity of the synthetic peptides were confirmed by a single peak in the analytical high performance liquid chromatogram (HPLC), capillary zone electrophoresis, fast-atom bombardment mass spectrometry (FAB-MS) on a VG Analytical ZAB2-SE which gave single molecular ions consistent with the correct sequences, and amino acid analyses which were within 10% of the predicted values for each residue. L- α -dipalmitoylphosphatidylcholine (DPPC) (>99% pure) was from Avanti Polar Lipids (Birmingham, AL). Using these procedures the following peptides were synthesized; their analytical properties are found in Table 1.

1(A). PREPARATION OF POLYPEPTIDE: HBB-Aoc-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 1) (HBB-Aoc = N α -hydroxy-di-t-butyl-benzoyl-aminoocatanoyl-)

Initially Aoc-Glu(OBzl)-Trp-Aib-Lys(N^E-2ClZ)-pMBHA was prepared by using a Lys(N^E-2ClZ)-pMBHA resin placed in ABI430A peptide synthesizer and synthesized using standard t-Boc chemistry. To synthesize peptide 1A, N α -hydroxy-di-t-butyl-benzoic acid (HBB) (501mg), dimethylformamide (4mL) and methylene chloride (4mL) were combined and a dicyclohexylcarbodiimide solution (8mL of a 0.5M solution in methylene chloride) was added and stirred for 5 minutes to give the symmetrical anhydride of HBB, which was then coupled to Aoc-Glu(OBzl)-Trp-Aib-Lys(N^E-2ClZ)-pMBHA in 10X excess per each of two couplings. The HBB-Aoc-Glu(OBzl)-Trp-Aib-Lys(N^E-2ClZ)-pMBHA protected peptide was cleaved from the resin and side chain protecting groups were removed by treating the HBB-peptide-resin in anhydrous HF containing 5% anisole and 5% dimethylsulfide at -5°C for 1 hour. The peptide was then extracted from the resin with 50% acetonitrile in 0.1% trifluoroacetic acid, frozen and

lyophilized. The peptide was then purified by reverse phase HPLC to give the title compound.

1(B). PREPARATION OF DPPC COMPLEX WITH POLYPEPTIDE
5 DESCRIBED IN EXAMPLE 1(A).

Peptide 1(A) is prepared as described above. DPPC (25 mg) in 1 ml of chloroform is dried under a stream of nitrogen and dried under vacuum to remove traces of organic solvent.
10 To the dry lipid mixture is added 3 ml of water. The preparation is incubated for 1 hour at 45°C. Then, 0.5 mg of dry peptide 1(A) is added to the aqueous preparation. The preparation is sonicated in a bath ultrasonicator at 45°C for 2 hours. The resulting lipid-peptide mixture is
15 lyophilized and stored at 4°C for up to one month. Prior to testing, 9 ml of 0.9% NaCl, 20 mM HEPES buffer, pH 7.40 is added. The preparation is incubated for 1 hour at 45°C with periodic mixing.

20

EXAMPLE 2

2(A). PREPARATION OF POLYPEPTIDE: HBB-Aoc-Glu-Trp-Glu-Lys-NH₂ (SEQ ID NO: 2) (HBB-Aoc = Na-hydroxy-di-t-butyl-benzoyl-aminoocatanoyl-)
25

Aoc-Glu(OBzl)-Trp-Glu(OBzl)-Lys(N^E-2ClZ)-pMBHA was prepared by using a Lys(N^E-2ClZ)-pMBHA resin placed in ABI430A peptide synthesizer and synthesized using standard t-Boc chemistry. To synthesize peptide 2A, Na-hydroxy-di-t-butyl-benzoic acid (HBB) (501mg), dimethylformamide (4mL) and
30 methylene chloride (4mL) were combined and a dicyclohexylcarbodiimide solution (8mL of a 0.5M solution in methylene chloride) was added and stirred for 5 minutes
35 to give the symmetrical anhydride of HBB, which was then

coupled to Aoc-Glu(OBzl)-Trp-Glu(OBzl)-Lys(N^E-2ClZ)-pMBHA in 4X excess per each of two couplings. The HBB-Aoc-Glu(OBzl)-Trp-Glu(OBzl)-Lys(N^E-2ClZ)-pMBHA protected peptide was cleaved from the resin and side chain protecting groups were removed by treating the HBB-peptide-resin in anhydrous HF containing 5% anisole and 5% dimethylsulfide at -5°C for 1 hour. The peptide was then extracted from the resin with 50% acetonitrile in 0.1% trifluoroacetic acid, frozen and lyophilized. The peptide was then purified by reverse phase HPLC to give the title compound.

2(B). PREPARATION OF DPPC COMPLEX WITH POLYPEPTIDE DESCRIBED IN EXAMPLE 2(A).

Peptide 2(A) was mixed with DPPC essentially as described under Example 1.

Example 3

3(A). PREPARATION OF POLYPEPTIDE: (Trl-Aoc-Glu-Trp-Aib-Lys-NH₂ (Trl-Aoc- = Na-hydroxy-di-t-butyl-benzoyl-aminoocatanoyl) (SEQ ID NO: 3).

Aoc-Glu(OBzl)-Trp-Aib-Lys(N^E-2ClZ)-pMBHA was prepared by using a Lys(N^E-2ClZ)-pMBHA resin placed in ABI430A peptide synthesizer using standard t-Boc chemistry.

To synthesize peptide 3A, 6-hydroxy-2,5,7,8,-tetramethylchroman-2-carboxylic acid (Trolox) (501mg), dimethylformamide (4mL) and methylene chloride (2.5mL) were combined and a dicyclohexylcarbodiimide solution (8mL) of a 0.5M solution in methylene chloride) was added and stirred for 5 minutes to give the symmetrical anhydride which was then coupled to Aoc-Glu(OBzl)-Trp-Aib-Lys(N^E-2ClZ)-pMBHA in 10X excess per each of two couplings.

To cleave Trl-Aoc-Glu(OBzl)-Trp-Aib-Lys(N^E-2ClZ)-pMBHA from the resin and remove side chain protecting groups, the peptide was treated with anhydrous HF, 5% anisole and 5% dimethylsulfide at -5°C for 1 hour. The Trl-peptide was extracted from the resin with 50% acetonitrile in 0.1% trifluoroacetic acid, frozen and lyophilized. The Trl-peptide was purified by reverse phase HPLC to give the title compound.

10

3(B). PREPARATION OF DPPC COMPLEX WITH POLYPEPTIDE DESCRIBED IN EXAMPLE 3(A).

Peptide 3(a) was prepared with DPPC essentially as described in Example 1b.

15

Example 4

4(A). PREPARATION OF POLYPEPTIDE: HBB-Glu-Trp-Aib-Lys-NH₂
(SEQ ID NO: 4) (HBB = N^α-hydroxy-di-t-butyl-benzoyl)

20

Peptide 4(A) is prepared in a manner essentially analogous to the preparation of peptide 1(A).

25 4(B). PREPARATION OF DPPC COMPLEX WITH POLYPEPTIDE DESCRIBED IN EXAMPLE 4(A).

Peptide 4(A) is mixed with DPPC essentially as described under Example 1.

30

35

Example 5

5(A). PREPARATION OF POLYPEPTIDE: HBB-Aoc-Glu-Trp-Ala-Lys-
5 NH₂ (SEQ ID NO: 5) (HBB-Aoc = Na-hydroxy-di-t-butyl-benzoyl-
aminoocatanoyl-)

Peptide 5(A) is prepared in a manner essentially
analogous to the preparation of peptide 1(A).

10

5(B). PREPARATION OF DPPC COMPLEX WITH POLYPEPTIDE
DESCRIBED IN EXAMPLE 4(A).

Peptide 5(A) is mixed with DPPC essentially as
described under Example 1.

15

TABLE 1
ANALYTICAL PROPERTIES OF PEPTIDES SYNTHESIZED
FABS-MASS SPECTROMETRY ANALYSIS OF PEPTIDES 1-7

20

<u>SEQ ID</u> <u>No:</u>	<u>PEPTIDE</u>	<u>FAB MS</u>	<u>AAA</u>
1	HBB-Aoc-Glu-Trp-Aib-Lys-NH ₂	[M + H] ⁺ = 920.6	@85%
2	HBB-Aoc-Glu-Trp-Glu-Lys-NH ₂	[M + H] ⁺ = 963.6	@62%
25	Trl-Aoc-Glu-Trp-Aib-Lys-NH ₂	[M + H] ⁺ = 920.6	@89%
4	HBB-Glu-Trp-Aib-Lys-NH ₂	[M + H] ⁺ = 778.97	@78%
5	HBB-Aoc-Glu-Trp-Ala-Lys-NH ₂	[M + H] ⁺ = 904	@76%

30

35

-29-

PREPARATION OF ANTIOXIDANT MOIETIES

The following antioxidant starting materials may be
5 used as described in the preceding examples.

Example 6PREPARATION OF STARTING MATERIAL ANTIOXIDANT COMPOUND:3-t-Butyl-5-methyl-4-hydroxybenzoic acid

10

Charge a reaction vessel with a suspension of sodium
hydride (4.74g, 0.198mol) in anhydrous ethylene glycol
dimethyl ether (150mL). Add, by dropwise addition, a
solution of 2-t-butyl-6-methylphenol (0.1mol) in ethylene
15 glycol dimethyl ether (150mL). Warm to 50-60°C for 1.5
hours then introduce carbon dioxide through a gas-
disparging tube below the surface of the reaction mixture
for 20 hours. Cool to 5°C and destroy the excess sodium
hydride carefully with methyl alcohol (30mL). After
20 hydrogen evolution ceases, adjust the pH of the reaction
mixture to 2 with 1N hydrochloric acid. Dilute with water
(1.6L) and collect the title compound by filtration.

Example 725 PREPARATION OF STARTING MATERIAL ANTIOXIDANT COMPOUND:(6-Hydroxy-7-t-butyl-5-isopropyl-8-propylchroman-2-
yl)acetic acid

Mix magnesium turnings (45mg, 1.85mmol) and 1-chloro-2,2-
30 dimethylpropane (74.6mg, 0.7mmol) in anhydrous ether (9mL).
Heat and stir vigorously, then add, by dropwise addition,
1,2-dibromoethane (156mg, 0.839mmol) in anhydrous ether
(1.5mL). Reflux for 12 hours, place under an argon
atmosphere and cool to 0-5°C. Add, by dropwise addition, a
35 solution of isobutyryl chloride (0.533mmol) in anhydrous

-30-

diethyl ether (1.5mL). Stir at 0-5°C for 1.5 hours, pour into a mixture of ice and concentrated hydrochloric acid (0.15mL) and separate the organic phase. Wash with ethyl acetate, 5% aqueous sodium carbonate and brine. Dry (MgSO₄) and evaporate the solvent *in vacuo* to give 2,2-6-trimethyl-4-heptanone.

Dissolve vinylmagnesium chloride (0.7mmol) in anhydrous diethyl ether (1mL), place under an argon atmosphere and cool to 1-5°C. Add, by dropwise addition, a solution of butyryl chloride (0.533mmol) in anhydrous diethyl ether (1.5mL). Stir at 0-5°C for 1.5 hours, pour into a mixture of ice and concentrated hydrochloric acid (0.15mL) and separate the organic phase. Wash with water, 5% aqueous sodium carbonate and brine. Dry (MgSO₄) and evaporate the solvent *in vacuo* to give propyl vinyl ketone.

Dissolve 2,2-6-trimethyl-4-heptanone (0.4mol) in methanol (10mL) and add potassium tert-butoxide (12g. 0.1mol). Add, by dropwise addition, a solution of propyl vinyl ketone (0.2mol) in methanol (10mL). Stir for 10 minutes and portion between ethyl ether and brine. Separate the organic phase and wash with brine until neutral. Dry (Na₂SO₄) and evaporate the solvent *in vacuo* to give 2-propyl-3-t-butyl-5-isopropylbenzoquinone.

Dissolve 2-propyl-3-t-butyl-5-isopropylbenzoquinone (10mmol), 1,1,3,3-tetramethyldisiloxane (1.79mL, 10mmol) and iodine (0.05g) in methylene chloride (30mL). Stir at reflux for 30 minutes and extract with 1N sodium hydroxide (30mL). Acidify the aqueous phase with concentrated hydrochloric acid and extract into ethyl acetate (4X10mL), dry (Na₂SO₄) and evaporate the solvent *in vacuo* to give 2-propyl-3-t-butyl-4-hydroxy-5-isopropylphenol.

35

Dissolve 2-propyl-3-t-butyl-4-hydroxy-5-isopropylphenol (2.0mol) and trimethyl orthoformate (0.3L) in methanol (1.2L) and degas. Place under a nitrogen atmosphere and cool to 3°C and add concentrated sulfuric acid (5mL). Add,
5 by dropwise addition, methyl vinyl ketone (340mL, 4.0mol) and stir without cooling for 44 hours. Pour into aqueous sodium hydrogen carbonate and extract into ethyl ether. Dry (MgSO₄) and evaporate the solvent *in vacuo* to give 2-methoxy-2-methyl-7-t-butyl-5-isopropyl-8-propyl-chroman-6-
10 ol.

Dissolve 2-methoxy-2-methyl-7-t-butyl-5-isopropyl-8-propyl-chroman-6-ol (2mol) in pyridine (600mL) and add acetic anhydride (900mL). Degas and stir under a nitrogen
15 atmosphere for 18 hours. Pour into ice/water and stir for 3 hours. Extract into ethyl ether, dry (MgSO₄), evaporate the solvent *in vacuo* and purify by chromatography to give 2-methoxy-2-methyl-7-t-butyl-5-isopropyl-8-propyl-chroman-6-yl-acetate.

20 Dissolve 2-methoxy-2-methyl-7-t-butyl-5-isopropyl-8-propyl-chroman-6-yl-acetate (2mol) in acetone (2.5L) and add water (2L) followed by concentrated hydrochloric acid (16.6mL). Distill the solvent from the stirred mixture until the head
25 temperature reaches 90°C. Cool the suspension, dilute with ethyl ether and wash with aqueous sodium hydrogen carbonate. Dry (MgSO₄), evaporate the solvent *in vacuo* and purify by chromatography to give 2-hydroxy-2-methyl-7-t-butyl-5-isopropyl-8-propyl-chroman-6-yl-acetate.

30

35

-32-

Suspend sodium hydride (47.2g of 56% in mineral oil, 1.10mol) in anhydrous tetrahydrofuran (1L). Place under a nitrogen atmosphere and add, by dropwise addition, 5 trimethyl phosphonoacetate (209.4g, 1.15mol). Stir the 25 minutes and add a solution of 2-hydroxy-2-methyl-7-t-butyl-5-isopropyl-8-propyl-chroman-6-yl-acetate (0.5mol) in tetrahydrofuran (1L). Stir at room temperature for 18 hour then heat at reflux for 4 hours. Cool, evaporate the 10 solvent *in vacuo* and purify by chromatography to give the title compound.

BIOLOGICAL

Methods of testing the synthetic surfactant 15 preparations for efficacy are well known in the art. For example, the synthetic surfactant preparations of the present invention can be tested in any appropriate manner such as in the adult rat lung model (Ikegami, et al., (1979) Pediatr. Res. 13, 777-780).

20

Pressure-volume characteristics of surfactant-depleted rat lungs are similar to those of lungs of infants with hyaline membrane disease and restoration of the pressure-volume relationship of the lung to normal is related to the 25 amount of surfactant instilled in a dose dependent manner. (Bermel, M.S., et al., Lavaged excised rat lungs as a model of surfactant deficiency, Lung 162: 99-113 (1984)).

Example 8

30

Isolated Rat Lavaged Lung Model

The experimental procedures for animal preparation, pressure-volume curve registration and lung lavage are adapted from those described by Ikegami et al., Pediatr. 35 Res. 11: 178-182 (1977) and Pediatr. Res. 13: 777-780

(1979, and Bermel et al, Lung 162: 99-113 (1984). Male Sprague Dawley rats (200-250 g) are anesthetized with sodium pentobarbital and exsanguinated. The trachea is cannulated and the thoracic organs are removed *en bloc*.

5 After removal of the adventitious tissue, the trachea and lungs (~2g) are suspended in saline (0.9%), placed in a vacuum chamber, and degassed according to the procedure of Stengel et al. the degassed lungs are suspended in saline in a 37°C, jacketed reservoir and the tracheal cannula is

10 connected both to a water manometer and a glass syringe by a T-tube. The glass syringe is placed in an infusion/withdrawal pump. Lungs are rapidly inflated with air to 30 cm H₂O pressure at the rate of 10 ml/min to minimize air trapping, and are maintained at this pressure

15 for 10 min by intermittently adding air to the lungs. The total volume of air infused is recorded as the total lung capacity (TLC) which is generally 14-15 ml. The lungs are then deflated at a rate of 2.5 ml/min until zero pressure is attained. During deflation, pressure is read from the

20 water manometer at 1 cm intervals and recorded. These data are used to construct a pressure-volume (P-V) or quasi-static compliance curve after correction for the P-V curve of the apparatus. After degassing and equilibration, the lungs are rendered surfactant-deficient by repeated lavage

25 with 5 ml/g lavage buffer (0.9% NaCl, 10 mM HEPES, pH 7.4). The procedures of degassing, equilibrating, and lavaging are repeated (15-20 times) until the pressure-volume curve had become distinctly sigmoidal in shape and the volume of air remaining in the lungs at 5 cm H₂O pressure is less than

30 or equal to 3 ml. At this point, the lungs are considered surfactant-deficient. For testing, 2 ml of 0.9% NaCl, 10 mM HEPES buffer, pH 7.4, are added to the dry lung surfactants (25 mg of phospholipid; 100-125 mg/kg) and the mixture is vortexed, flushed with nitrogen and incubated

35 for 1 h at 45°C. The mixture is then vortexed again,

-34-

degassed if foamy, and 2 ml of the test mixture are introduced into and withdrawn from the lungs four times by syringe. When the test mixture is reintroduced to the lungs for the fifth time, it is allowed to remain in the lungs. This procedure is adopted to encourage even distribution of the material throughout the lung. The lungs are degassed, allowed to equilibrate at 37°C for 5 min, and a P-V measurement is performed. Lungs are studied while supported in saline at 37°C as opposed to ambient temperature since the physical characteristics of the surfactants may be dependent upon temperature. Canine lung surfactant is administered in a similar manner except that the surfactant is heated for only 5 min. Data are presented in terms of the %TLC. The deflation limbs of the pressure-volume (P-V) curves in adult rat lungs are analyzed by calculating the total lung capacities (%TLC) at 5 and 10 cm H₂O pressure (PC₅ and PC₁₀). Comparisons are based on per cent restoration = $(PC_{5(sufficient)} - PC_{5(test)} \times 100 / (PC_{5(sufficient)} - PC_{5(deficient)})$ and made by one-way analysis of variance using the general linear models procedure with specific contrasts of the means (SAS Institute Inc., Cary, NC). Lavage and treatment with test mixtures did not produce a change in the absolute TLC of greater than 6%.

25

Results

The preparations administered to the rat had a translucent appearance. The deflation limb of the pressure-volume (P-V) curve in adult rat lungs was analyzed by calculation of the per cent of total lung capacity (TLC) at 5 cm H₂O pressure (PC₅) and the TLC at 10 cm H₂O (PC₁₀). The restoration based upon the PC₅ values was used to compare the test mixtures. DPPC alone had no significant effect on the pressure-volume (P-V) curves of the lavaged

35

lung. Activities of peptide-DPPC mixtures are indicated in Table 2.

TABLE 2
Efficacy of Synthetic Surfactants in The
Adult Rat Lavaged Lung Model

Mixture	n	PC ₅ (%TLC)	PC ₁₀ (%TLC)	RESTORATION %
sufficient	50	68±1	87±1	100
deficient	50	17±1	45±1	0
DPPC	4	13±1	31±2	-11±8
SEQ ID No: 1 HBB-Aoc-Glu-Trp-Aib-Lys-NH ₂	2	48±5	73±3	65±5
SEQ ID No: 2 HBB-Aoc-Glu-Trp-Glu-Lys-NH ₂	3	52±2	75±2	83±5
SEQ ID No: 3 Trl-Aoc-Glu-Trp-Aib-Lys-NH ₂	2	33±2	59±2	43±6
SEQ ID No: 5 HBB-Aoc-Glu-Trp-Ala-Lys-NH ₂	3	55±4	77±2	81±7

-36-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: McLean, Larry R
Edwards, Judson V
- (ii) TITLE OF INVENTION: Synthetic Peptide Lung Surfactants
Having Covalently Bonded Antioxidants
- (iii) NUMBER OF SEQUENCES: 5
- 10 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Marion Merrell Dow Inc.
(B) STREET: 2110 East Galbraith Rd.
(C) CITY: Cincinnati P. O. Box 156300
(D) STATE: Ohio
(E) COUNTRY: USA
(F) ZIP: 45215-6300
- 15 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- 20 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 07/923,092
(B) FILING DATE: 31-JUL-1992
- 25 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Collier, Kenneth J
(B) REGISTRATION NUMBER: 34,982
(C) REFERENCE/DOCKET NUMBER: M01582 US
- 30 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (513) 948-7834
(B) TELEFAX: (513) 948-7961
(C) TELEX: 214320

35

-37-

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 1

(D) OTHER INFORMATION: /note=
"Xaa=N-alpha-[N-(8-hydroxy-di-t-butyl-benzoyl)-am
ino octanoic]-glutamic acid (HBB-Aoc-Glu)"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 3

(D) OTHER INFORMATION: /note= "Xaa=2-amino-isobutyric acid
(Aib)"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 4

(D) OTHER INFORMATION: /note= "Xaa=lysin-1-amide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Trp Xaa Xaa
1

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: 1

(D) OTHER INFORMATION: /note=
"Xaa=N-alpha-[N-(8-hydroxy-di-t-butyl-benzoyl)-am
ino octanoic]-glutamic acid (HBB-Aoc-Glu)"

-38-

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "Xaa=lysin-1-amide"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Xaa Trp Glu Xaa
1

(2) INFORMATION FOR SEQ ID NO:3:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

15

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note=
"Xaa=N-alpha-[N-(6-hydroxy-2,5,7,8-tetramethyl-ch
roman-2-carboxylic acid)-amino octanoic]"

20

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "(cont'd) -glutamic acid
(Trl-Aoc-Glu)"

(ix) FEATURE:

25

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "Xaa=2-amino-isobutyric acid
(Aib)"

(ix) FEATURE:

30

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "Xaa=lysin-1-amide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Xaa Glu Trp Xaa Xaa
1 5

35

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note=

10

"Xaa=N-alpha-[N-(8-hydroxy-di-t-butyl-benzoyl)-glutamic acid (HBB-G..."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "Xaa=2-amino-isobutyric acid (Aib)"

15

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "Xaa=lysine-1-amide"

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Xaa Trp Xaa Xaa
1

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

30

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "Xaa=N-alpha-[N-(8-hydroxy-di-t-butyl-benzoyl)-amino octanoic]-glutamic acid (HBB-Aoc-Glu)"

35

-40-

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 4

(D) OTHER INFORMATION: /note= "Xaa=lysin-1-amide"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Xaa Trp Ala Xaa

1

10

15

20

25


30

35

WHAT IS CLAIMED IS:

1. A polypeptide of formula:

5



or an optically active isomer or pharmaceutically acceptable salt thereof; wherein

10

A₁ is a bond or negatively charged amino acid selected from Glu or Asp;

A₂ is a hydrophobic amino acid selected from Trp, Tyr, Phe, His, Val, Leu, or Ile;


A₃ is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and

15


A₄ is a positive charged amino acid selected from Lys, Arg, or His;

X is of formula Da or Db:

20



Da



or

Db

25

wherein, B₁ is B, -C(O)-, -B-C(O)-, -C(O)-NH-B-C(O)-; and B is a bond, C₁₋₁₆ alkylene, or C₂₋₁₆ alkenylene; and wherein each R₁, R₂, R₃, R₄, R₅, R₆ and R₇ is independently a C₁₋₆ alkyl;


30

Y is a carboxyl substituent of A₄ selected from hydroxy, amino, alkylamino, and alkoxy groups; and

wherein, when A₃ is a bond, A₁ and A₂ may be interchanged.

35

2. A polypeptide of formula:



or an optically active isomer or pharmaceutically acceptable salt thereof; wherein


A₁ is a bond or negatively charged amino acid selected from Glu or Asp;

A₂ is a hydrophobic amino acid selected from Trp, Tyr, Phe, His, Val, Leu, or Ile;


A₃ is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and

A₄ is a positive charged amino acid selected from Lys, Arg, or His;

X is of formula Da or Db:



Da




Db

wherein, B₁ is B, -C(O)-, -B-C(O)-, -C(O)-NH-B-C(O)-; and B is a bond, C₁₋₁₆ alkylene, or C₂₋₁₆ alkenylene; and wherein each R₁, R₂, R₃, R₄, R₅, R₆ and R₇ is independently a C₁₋₆ alkyl;

Y is a carboxyl substituent of A₄ selected from hydroxy, amino, alkylamino, and alkoxy groups.

3. A polypeptide of formula:



or an optically active isomer or pharmaceutically acceptable salt thereof; wherein


A₁ is a bond or Glu;

A₂ is Trp or Glu;


A₃ is Aib, Glu, Gln, Leu, Ala or Orn; and

A₄ is Lys;

X is of formula Da or Db:



Da



Db

wherein B₁ is B, -C(O)-, -B-C(O)-, -C(O)-NH-B-C(O)-; and B is a bond, C₁₋₁₆ alkylene, or C₂₋₁₆ alkenylene; and wherein each R₁, R₂, R₃, R₄, R₅, R₆ and R₇ is independently a C₁₋₆ alkyl; and

Y is a carboxyl substituent of A₄ selected from hydroxy, amino, alkylamino, and alkoxy groups.

4. A polypeptide as in one of claims 1-3, in which A₁ is a Glu.

5. A polypeptide as in one of claims 1-3, in which A₂ is a Trp.

-44-

6. A polypeptide as in one of claims 1-3, in which A₃ is a Aib.

5 7. A polypeptide as in one of claims 1-3, in which A₃ is a Ala.

8. A polypeptide as in one of claims 1-2, in which A₄ is a Lys.

10 9. A polypeptide of one of claims 1 - 16 wherein Y is an amino.

15 10. A polypeptide as in one of claims 1-3, in which X is Da.

11. A polypeptide as in one of claim 17 or 18 in which each of R₁ and R₂ is tert-butyl.

20 12. A polypeptide as in one of claims 1-3, which is HBB-Aoc-Glu-Trp-Aib-Lys-NH₂. (SEQ ID NO: 1).

13. A polypeptide as in one of claims 1-3, which is HBB-Aoc-Glu-Trp-Glu-Lys-NH₂. (SEQ ID NO: 2).


25 14. A polypeptide as in one of claims 1-3, which is Trl-Aoc-Glu-Trp-Aib-Lys-NH₂. (SEQ ID NO: 3).

30 15. A polypeptide as in one of claims 1-3, which is HBB-Glu-Trp-Aib-Lys-NH₂. (SEQ ID NO: 4).

16. A polypeptide as in one of claims 1-3, which is HBB-Aoc-Glu-Trp-Ala-Lys-NH₂. (SEQ ID NO: 5).

35

17. A complex of a polypeptide of the formula:



or an optically active isomer or pharmaceutically acceptable salt thereof; wherein


A₁ is a bond or negatively charged amino acid selected from Glu or Asp;

A₂ is a hydrophobic amino acid selected from Trp, Tyr, Phe, His, Val, Leu, or Ile;


A₃ is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and

A₄ is a positive charged amino acid selected from Lys, Arg, or His;

X is of formula Da or Db:



Da




Db

wherein, B₁ is B, -C(O)-, -B-C(O)-, -C(O)-NH-B-C(O)-; and B is a bond, C₁₋₁₆ alkylene, or C₂₋₁₆ alkenylene; and wherein each R₁, R₂, R₃, R₄, R₅, R₆ and R₇ is independently a C₁₋₆ alkyl;

Y is a carboxyl substituent of A₄ selected from hydroxy, amino, alkylamino, and alkoxy groups; and

wherein, when A₃ is a bond, A₁ and A₂ may be interchanged; and a lipid or mixture of lipids selected from the group consisting of DPPC, PC, CL, PG, PS, FA and TG.

18. A complex of a polypeptide of the formula:



5 or an optically active isomer or pharmaceutically acceptable salt thereof; wherein

A_1 is a bond or negatively charged amino acid selected from Glu or Asp;


A_2 is a hydrophobic amino acid selected from Trp, Tyr, Phe, His, Val, Leu, or Ile;

10 A_3 is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and


A_4 is a positive charged amino acid selected from Lys, Arg, or His;

X is of formula Da or Db:

15



Da



Db

20

25

wherein, B_1 is B, $-C(O)-$, $-B-C(O)-$, $-C(O)-NH-B-C(O)-$; and B is a bond, C_{1-16} alkylene, or C_{2-16} alkenylene; and wherein each R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 is independently a C_{1-6} alkyl;

30

Y is a carboxyl substituent of A_4 selected from hydroxy, amino, alkylamino, and alkoxy groups; and a lipid or mixture of lipids selected from the group consisting of DPPC, PC, CL, PG, PS, FA and TG.

35

19. A complex as in claim 17 or 18 in which DPPC comprises the major component of the lipid.

5 20. A complex as in claim 17 or 18 in which the lipid is a mixture of DPPC and PG.

21. A complex as in claim 17 or 18 in which the lipid consists of from about 85-100% DPPC and from about 0-15%
10 PG.

22. A complex as in claim 17 or 18 in which the polypeptide is HBB-Aoc-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 1).

15 23. A complex as in claim 17 or 18 in which the polypeptide is HBB-Aoc-Glu-Trp-Glu-Lys-NH₂ (SEQ ID NO: 2).

24. A complex as in claim 17 or 18 in which the polypeptide is Trl-Aoc-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 3).
20

25. A complex as in claim 17 or 18 in which the polypeptide is HBB-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 4).


26. A complex as in claim 17 or 18 in which the
25 polypeptide is HBB-Aoc-Glu-Trp-Ala-Lys-NH₂ (SEQ ID NO: 5).

30

35

-48-

27. A method of treating respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of a complex of a polypeptide of the formula:



or an optically active isomer or pharmaceutically acceptable salt thereof; wherein


A_1 is a bond or negatively charged amino acid selected from Glu or Asp;

A_2 is a hydrophobic amino acid selected from Trp, Tyr, Phe, His, Val, Leu, or Ile;


A_3 is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and

A_4 is a positive charged amino acid selected from Lys, Arg, or His;

X is of formula Da or Db:



Da



Db

wherein, B_1 is B, $-C(O)-$, $-B-C(O)-$, $-C(O)-NH-B-C(O)-$; and B is a bond, C_{1-16} alkylene, or C_{2-16} alkenylene; and wherein each R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 is independently a C_{1-6} alkyl;


Y is a carboxyl substituent of A_4 selected from hydroxy, amino, alkylamino, and alkoxy groups; and

wherein, when A₃ is a bond, A₁ and A₂ may be
interchanged; and a lipid or mixture of lipids
selected from the group consisting of DPPC, PC, CL,
PG, PS, FA and TG.

5

28. A method of treating respiratory distress syndrome
in a subject in need thereof which comprises administering
to the subject an effective amount of a complex of a
polypeptide of the formula:

10



or an optically active isomer or pharmaceutically
acceptable salt thereof; wherein

15

A₁ is a bond or negatively charged amino acid
selected from Glu or Asp;

A₂ is a hydrophobic amino acid selected from Trp,
Tyr, Phe, His, Val, Leu, or Ile;


A₃ is Aib, Glu, Gln, Leu, Ala, Orn or a bond; and

20


A₄ is a positive charged amino acid selected from
Lys, Arg, or His;

X is of formula Da or Db:

25



Da



Db

30

wherein, B₁ is B, -C(O)-, -B-C(O)-, -C(O)-NH-B-
C(O)-; and B is a bond, C₁₋₁₆ alkylene, or C₂₋₁₆
alkenylene; and wherein each R₁, R₂, R₃, R₄, R₅,
R₆ and R₇ is independently a C₁₋₆ alkyl;

35

-50-

Y is a carboxyl substituent of A₄ selected from hydroxy, amino, alkylamino, and alkoxy groups; and a lipid or mixture of lipids selected from the group consisting of DPPC, PC, CL, PG, PS, FA and TG.

5

29. A method as in claim 27 or 28 in which DPPC comprises the major component of the lipid.

10 30. A method as in claim 27 or 28 in which the lipid is a mixture of DPPC and PG.

31. A method as in claim 27 or 28 in which the lipid consists of from about 85-100% DPPC and from about 0-15%
15 PG.

32. A method as in claim 27 or 28 in which the polypeptide is HBB-Aoc-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 1).

20 33. A method as in claim 27 or 28 in which the polypeptide is HBB-Aoc-Glu-Trp-Glu-Lys-NH₂ (SEQ ID NO: 2).


34. A method as in claim 27 or 28 in which the polypeptide is Trl-Aoc-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 3).
25

35. A method as in claim 27 or 28 in which the polypeptide is HBB-Glu-Trp-Aib-Lys-NH₂ (SEQ ID NO: 4).

36. A method as in claim 27 or 28 in which the
30 polypeptide is HBB-Aoc-Glu-Trp-Ala-Lys-NH₂ (SEQ ID NO: 5).


35

Figure 1



succinyl-Leu-Leu-Glu-Lys-Leu-Leu-Glu-Trp-Leu-Lys-NH₂

Figure 2



HBB-Aoc-Glu-Trp-Ala-Lys-NH₂

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07K5/10;	C07K5/08;	C07K5/06; A61K37/02
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P, X	WO, A, 9 308 824 (MERRELL DOW PHARMACEUTICALS INC.) 13 May 1993 see claims; examples ---	1-36
P, A	EP, A, 0 512 899 (ADIR ET COMPAGNIE) 11 November 1992 see page 7, line 51 - line 57 see page 8, line 3 - line 7; claim 1; examples 195, 196 ---	1
A	EP, A, 0 348 967 (MERREL DOW PHARMACEUTICALS INC.) 3 January 1990 see page 2, line 39 - line 51; claims; examples --- -/--	1-3, 17-19, 27-31
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
25 OCTOBER 1993		05 -11- 1993
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		FUHR C.K.B.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>US,A,4 861 756 (R.L. JACKSON) 29 August 1989</p> <p>see column 1, line 14 - line 64 see column 3, line 11 - line 45; claims; examples</p> <p style="text-align: center;">---</p>	<p>1-3, 17-19, 27-31</p>
A	<p>BIOCHEMISTRY vol. 30, no. 1, 8 January 1991, EASTON, PA US pages 31 - 37 L.R. MCLEAN ET AL. 'Minimal Peptide Length for Interaction of Amphipathic alpha-Helical Peptides with Phosphatidylcholine Liposomes' see introduction on page 31 see page 34, left column, last paragraph; table I</p> <p style="text-align: center;">---</p>	<p>1-3, 17-19</p>
P,A	<p>EP,A,0 529 568 (MERRELL DOW PHARMACEUTICALS INC.) 3 March 1993 see page 5, line 48 - line 54; claims; examples</p> <p style="text-align: center;">-----</p>	<p>1</p>

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark : Although claims 27-36 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9306249
SA 76671

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25/10/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9308824	13-05-93	AU-A- 2778392	07-06-93
EP-A-0512899	11-11-92	FR-A- 2676056 AU-A- 1594892	06-11-92 05-11-92
EP-A-0348967	03-01-90	AU-B- 617827 AU-A- 3722789 JP-A- 2053798	05-12-91 04-01-90 22-02-90
US-A-4861756	29-08-89	None	
EP-A-0529568	03-03-93	AU-A- 2106592 JP-A- 5213991	25-02-93 24-08-93

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.